

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EC Healthcare

醫思健康

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2138)

**SUPPLEMENTAL ANNOUNCEMENT
IN RELATION TO
SUBSCRIPTION OF SHARES IN JOINT VENTURE COMPANY FOR
BUILDING A NEW COMMERCIAL PROPERTY TO BE LEASED AND USED
AS MEDICAL CENTRE**

Reference is made to the announcement of EC Healthcare (the “**Company**”) dated 6 June 2022 in relation to the subscription of shares in the JV Company for building a new commercial property to be leased and used as medical centre (the “**Announcement**”). Terms used herein shall have the same meanings as defined in the Announcement unless otherwise stated.

The Company would like to provide below supplemental information in relation to the ultimate beneficial owners of the existing shareholders of the JV Company.

ULTIMATE BENEFICIAL OWNER OF KL1, KL2 AND KAILONG GROUP

As disclosed in the Announcement, KL1 and KL2 are subsidiaries of the investment funds managed by KaiLong Group, one of the region's leading real estate investment management companies.

The funds ultimately holding KL1 and KL2 are KaiLong Greater China Real Estate Fund II, L.P. registered in the Cayman Islands (“**KL1 Fund**”) and KaiLong Greater China Real Estate Fund II S.C.Sp. registered in Luxembourg (“**KL2 Fund**”) respectively. The general partner of KL1 Fund is KaiLong Greater China Real Estate Fund II GP Limited (“**KL1 GP**”), a limited company incorporated in the Cayman Islands and the general partner of KL2 Fund is KaiLong Greater China Real Estate Fund II GP SARL (“**KL2 GP**”), a limited company incorporated in Luxembourg.

Based on the information provided by KL1 and KL2, the largest ultimate beneficial owner of each of KaiLong Group, KL1 GP and KL2 GP (collectively, “**KaiLong**”) is Mr. Sun Dong Ping, who holds approximately 26.4% interest of KaiLong as at the date of the Announcement. Each of all other ultimate beneficial owners of KaiLong holds less than 25% interest in KaiLong.

Saved as disclosed above, all other information as set out in the Announcement remains unchanged and shall continue to be valid for all purposes. This announcement is supplemental

to and should be read in conjunction with the Announcement.

By order of the Board
EC Healthcare
Raymond Siu
Company Secretary

Hong Kong, 1 August 2022

As at the date of this announcement, the executive Directors are Mr. Tang Chi Fai, Mr. Lu Lyn Wade Leslie, Mr. Lee Heung Wing, Ms. Wong Ka Ki Ada and Mr. Wong Chi Cheung, the non-executive Director is Mr. Luk Kun Shing Ben, and the independent non-executive Directors are Mr. Ma Ching Nam, Mr. Look Andrew and Mr. Lam Chi Hang Josekin.